Confirm or not a “Star”
Context
- Company A acquired by B for its commercial network and manufacturing capacities.
- A is global leader in one Diagnostic segment with 2 (manual) Research solutions, not the B focus.
- B is a leading company active in routine IVD market with CE-marked automated solution.
- Clinical value of Diagnostic A is still under review by scientific community.
Mission
- B is considering either to invest or divest in Diagnostic A:
- To support the board decision, a global opportunity plan / due-diligence is requested starting from pathology state-of-art, development to commercial implementation and involving scientists, KOLs, developers, QA/RA, Finance, Marketing.
Deliverable : 10-year master plan including
- Pathology: current consensus through literature & KOLs, Epidemiology and trends.
- New product design supporting the current commercial unmet needs and volume.
- Different scenarios (aggressive, conservative, realistic) with financial projections based on set of assumptions.
- A 5-year plan to progressively phase-out previous technologies and switch to new development respecting different current on-going commitments.
Decision (Board of Directors)
- Investment in the franchise A with high priority.